↓ Skip to main content

Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery

Overview of attention for article published in International Journal of Nanomedicine, August 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter
3 X users
patent
1 patent
googleplus
1 Google+ user

Citations

dimensions_citation
68 Dimensions

Readers on

mendeley
66 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery
Published in
International Journal of Nanomedicine, August 2015
DOI 10.2147/ijn.s87145
Pubmed ID
Authors

Sang Joon Lee, Young-Il Jeong, Hyung-Kyu Park, Dae Hwan Kang, Jong-Suk Oh, Sam-Gyu Lee, Hyun Chul Lee

Abstract

Since cancer cells are normally over-expressed cathepsin B, we synthesized dendrimer-methoxy poly(ethylene glycol) (MPEG)-doxorubicin (DOX) conjugates using a cathepsin B-cleavable peptide for anticancer drug targeting. Gly-Phe-Leu-Gly peptide was conjugated with the carboxylic acid end groups of a dendrimer, which was then conjugated with MPEG amine and doxorubicin by aid of carbodiimide chemistry (abbreviated as DendGDP). Dendrimer-MPEG-DOX conjugates without Gly-Phe-Leu-Gly peptide linkage was also synthesized for comparison (DendDP). Nanoparticles were then prepared using a dialysis procedure. The synthesized DendGDP was confirmed with (1)H nuclear magnetic resonance spectroscopy. The DendDP and DendGDP nanoparticles had a small particle size of less than 200 nm and had a spherical morphology. DendGDP had cathepsin B-sensitive drug release properties while DendDP did not show cathepsin B sensitivity. Further, DendGDP had improved anticancer activity when compared with doxorubicin or DendDP in an in vivo CT26 tumor xenograft model, ie, the volume of the CT26 tumor xenograft was significantly inhibited when compared with xenografts treated with doxorubicin or DendDP nanoparticles. The DendGDP nanoparticles were found to be relatively concentrated in the tumor tissue and revealed stronger fluorescence intensity than at other body sites while doxorubicin and DendDP nanoparticles showed strong fluorescence intensity in the various organs, indicating that DendGDP has cathepsin B sensitivity. DendGDP is sensitive to cathepsin B in tumor cells and can be used as a cathepsin B-responsive drug targeting strategy. We suggest that DendGDP is a promising vehicle for cancer cell targeting.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 66 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 20%
Student > Master 8 12%
Student > Doctoral Student 6 9%
Student > Bachelor 5 8%
Student > Postgraduate 5 8%
Other 11 17%
Unknown 18 27%
Readers by discipline Count As %
Chemistry 11 17%
Pharmacology, Toxicology and Pharmaceutical Science 11 17%
Biochemistry, Genetics and Molecular Biology 6 9%
Medicine and Dentistry 4 6%
Agricultural and Biological Sciences 3 5%
Other 8 12%
Unknown 23 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2020.
All research outputs
#6,495,301
of 25,373,627 outputs
Outputs from International Journal of Nanomedicine
#655
of 4,123 outputs
Outputs of similar age
#69,215
of 276,419 outputs
Outputs of similar age from International Journal of Nanomedicine
#12
of 141 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 4,123 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,419 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 141 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.